Skip to main content

Table 4 Subgroup analysis of safety according to ICI therapy types

From: Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

 

Anti-PD (L)-1 Mono-Therapy

Anti-PD (L)-1 plus Chemotherapy

HIV (16)

HBV/HCV (30)

HIV (5)

HBVC/HCV(3)

Any Grade irAEs

N (%)

Grade ≥ 3 irAEs

N (%)

Any

Grade irAEs

N (%)

Grade

≥3

irAEs

N (%)

Any Grade irAEs

N (%)

Grade ≥ 3 irAEs

N (%)

Any Grade irAEs

N (%)

Grade ≥ 3 irAEs

N (%)

Total

4 (25)

3(19)

13(43)a

8(27)a

1(20)

0

1(33)

1(33)

Colitis

0

0

2

2

0

0

1

1

Hepatitis

2

1

6

4

0

0

0

0

Rash

2

0

6

1

1

0

0

0

Hypothyroidism

2

0

1

0

1

0

0

0

Pneumonitis

2

2

1

0

0

0

0

0

Arthritis

0

0

2

0

0

0

0

0

Diabetes Mellitus

0

0

1

1

0

0

0

0

Encephalitis

0

0

1

0

0

0

0

0

  1. aTwo patients with baseline grade ≥ 2 hepatitis